AURA BIOSCIENCES

Website http://www.aurabiosciences.com

Founded 2009

Employees 8

Overview

Aura Biosciences is a drug development oncology company . The technology is based on synthetic viruses that can target drugs to tumors with a unique mechanism of action. We have a solid IP portfolio, with an exclusive license from the National Cancer Institute. Our lead candidate is in late pre-clinical development for a rare cancer indication, ocular melanoma. We have key support from seasoned pharma investors including Henri Termeer.

Management Team

FOUNDING CEO

Elisabet de los Pinos

Eli is the founding CEO . Prior to Aura, she was part of Eli Lilly's leadership team responsible for Alimta’s market launch in Europe. Eli holds a Ph.D. in Molecular Biology from the University of Barcelona, and is a fellow of the Entrepreneurship Development Program at MIT Sloan School of Management . She is a Tech Pioneer at the World Economic Forum and a member of the Board of Overseers at the Museum of Science in Boston.

Interim Head Clinical Development

Peter Elliott

Peter holds a BSc in Pharmacology from London University and a PhD from Cambridge University . Peter was VP of Pharmacology and Development at Millenium and was a co-developer of Velcade©. Peter was then SVP of Research & Development at Sirtris where he led their programs dedicated to the discovery and development drugs for metabolic disorders, oncology, inflammation and neurodegenerative disorders.

Director of Research

John MacDougall

John received a B.Sc. in Toxicology from the University of Guelph (Canada) and a Ph.D. in Cancer Biology at the University of Toronto (Canada). He later joined Infinity Pharmaceuticals leading its pre-clinical pharmacology group. At Infinity, John’s team was responsible for executing discovery and IND enabling studies to support drug candidate selection and mechanistic understanding of Infinity’s portfolio of agents.

Director of Manufacturing

Andrew Russell

Andrew received a B.Sc in Biochemistry from the University of Liverpool (UK) and an M.Sc and Ph.D in Biochemical Engineering from the University of London (UK). Andrew spent 28 years at Eli Lilly in Bioprocess Development, Commercialization and Manufacturing. He is technical expert in conventional fermentation technology bioprocess scale-up, validation and operation. Products where he has played significant roles include Forteo® , Humulin®, Hu